Microbot Medical Showcases a Working Prototype of its Self-Cleaning Shunt
January 17 2019 - 8:32AM
Microbot Medical Inc. (Nasdaq CM: MBOT) demonstrated an activated
Self-Cleaning Shunt (SCSTM) during recent one-on-one investor and
analyst meetings in San Francisco, which took place during the same
week as the JP Morgan Healthcare conference. The Company’s SCSTM
was activated from a working prototype of its customized headset
that is intended to be used periodically by either the patient or
the healthcare provider for the operation of the SCSTM.
“Following our recent successful lab and
pre-clinical testing of the SCSTM, coupled with the progress we
made with the development of our SCSTM device, we are pleased to
see the enormous interest and positive feedback from the
professional community as we start exposing them to the device,”
commented Harel Gadot, President, Chief Executive Officer and
Chairman of Microbot.
These small-group demonstrations followed a live
demonstration of the headset at the International Society for
Hydrocephalus and Cerebrospinal Fluid Disorders (ISHCFD) annual
meeting held in Bologna, Italy in October 2018. The ISHCFD
was also the first time that, in front of leading global
neurologists, the Company’s pre-clinical study results were
presented by Professor Pat McAllister, Department of Neurosurgery,
Washington University School of Medicine, St. Louis. Dr.
McAllister’s presentation was titled “Biocompatibility of
the Novel Microbot Medical SCSTM
Shunt Catheter” and was part of the Company’s
participation at the annual meeting. It highlighted:
- In-vitro study performed at Wayne
State University, which supports the SCSTM’s potential as a viable
technology for preventing occlusion in shunts used to treat
hydrocephalus.
- In-vivo animal study performed at
Washington University School of Medicine in St. Louis, which
supports the safety profile of the Company’s SCSTM as a CSF
catheter.
The Company’s innovative SCSTM is designed to
prevent obstruction in the cerebrospinal fluid (CSF) catheters
implanted in the ventricle of the brain of patients who suffer from
hydrocephalus or Normal Pressure Hydrocephalus (NPH).
About Microbot Medical, Inc.
Microbot™, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
technological platforms, ViRobTM, TipCATTM and CardioSertTM, are
comprised of three highly advanced technologies, from which the
Company is currently developing its first product candidate: the
Self Cleaning Shunt, or SCSTM, for the treatment of hydrocephalus
and Normal Pressure Hydrocephalus, or NPH; and focusing on the
development of a Multi Generation Pipeline Portfolio (MGPP)
utilizing all technologies. Further information about Microbot
Medical is available at http://www.microbotmedical.com.
The ViRobTM technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to
navigate and crawl in different spaces within the human body,
including blood vessels, the digestive tract and the respiratory
system. Its unique structure gives it the ability to move in
tight spaces and curved passages as well as the ability to remain
within the human body for prolonged time. To learn more about
ViRobTM please visit
http://www.microbotmedical.com/technology/virob/.
TipCATTM is a transformational self-propelled,
flexible, and semi-disposable locomotive device providing see &
treat capabilities within tubular lumens in the human body such as
the colon, blood vessels, and the urinary tract. Its
locomotion mechanism is perfectly suitable to navigate and crawl
through natural & artificial tubular lumens, applying the
minimal necessary pressure to achieve the adequate friction
required for gentle, fast, and safe advancement within the human
body. To learn more about TipCATTM, visit
http://www.microbotmedical.com/technology/tipcat/.
CardioSertTM technology contemplates a unique
combination of a guidewire and microcatheter, technologies that are
broadly used for endoluminal surgery. The CardioSertTM technology
features unique steering and stiffness control capabilities, and it
was originally developed to support interventional cardiologists in
crossing the most complex lesions called chronic total occlusion
(CTO) during percutaneous coronary intervention (PCI) procedures
and has the potential to be used in other spaces and applications,
such as peripheral intervention, neurosurgery and urology.
CardioSertTM was part of a technological incubator supported by the
Israel Innovation Authorities (formerly known as the Office of the
Chief Scientist, or OCS), and its device has successfully completed
pre-clinical testing.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory
approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contacts:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/6cbefe74-c29c-4f55-a596-c54e0b805ef1
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024